SAN DIEGO--(BUSINESS WIRE)--Ardea Biosciences, Inc. (Nasdaq:RDEA) today announced that the Company will present data from preclinical studies of RDEA119, its lead mitogen-activated ERK kinase (MEK) inhibitor in development for the treatment of cancer, demonstrating synergy when administered in combination with multiple anti-cancer agents, at the American Association for Cancer Research 100th Annual Meeting 2009 in Denver, Colorado.
